January 22, 2021
Taisho Pharmaceutical said on January 21 that it has launched a PIII clinical trial in Japan for its SGLT2 inhibitor Lusefi (luseogliflozin) for the treatment of children with type 2 diabetes. The double-blind, placebo-controlled study will look into the safety...read more